Your local Pfizer representative/Healthcare Partnership Manager can provide you with guidance on how to initiate NGENLA for your patients. Access guidance on how to contact us here.
Newly diagnosed paediatric Growth Hormone Deficiency (pGHD) patients
NGENLA is indicated for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of Growth Hormone (GH). The recommended dose is 0.66 mg/kg body weight administered once weekly by subcutaneous injection.1
Current pGHD patients who are currently on daily GH
Consider NGENLA for your pGHD patients aged 3 years or older who are currently on daily GH treatment, and may benefit from once-weekly treatment. These may include:
• Patients who prefer a less frequent injection schedule
• Patients currently on a daily GH, who are transitioning to injecting themselves.
For patients switching from daily growth hormone, therapy with NGENLA may be initiated at a dose of 0.66mg/kg/week on the day following their last daily growth hormone injection.1
NGENLA delivered a favoured treatment experience for patients and caregivers in a phase 3 crossover study versus daily Genotropin (somatropin) in pGHD, based on lower treatment burden as shown by less life interference, using a range of parameters.
Life interference parameter overall mean scores where patients and caregivers favoured once weekly NGENLA (95% CI) after 12 weeks vs. once daily Genotropin included: willingness to continue treatment, impact on daily activities, caregiver & family life interference and convenience & ease of the injection schedule.
For safety & efficacy data click here.
Efficacy and Safety
Dosing and Storage
Access the document to support initiation of NGENLA.
The NGENLA team are here to support you with any queries. Find out how you can get in touch.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
OK, We will need you to sign in before we can determine if you are aligned with a Pﬁzer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?